Mercy Medical Center launches new study.
April 02, 2010
Colloquium member hospital, Mercy Medical Center of Canton, Ohio has been chosen to launch a study titled “The Role of Corvalen®® on Hospital Readmission Rates in Patients with NYHA Class III and IV Heart Failure” in partnership with Bioenergy Life Science, Inc.
The primary objective of the trial is to demonstrate that Corvalen® supplementation in patients with the primary or secondary diagnosis of heart failure will reduce the hospital readmission rate.
Corvalen® is a medical food containing D-Ribose, a pentose sugar crucial to adenosine nucleotide metabolism. Previously, D-Ribose has been shown to improve diastolic function and myocardial performance scores as well as ventilatory efficiency, oxygen uptake.
Enrollment is for a six month period. Subjects take D-Ribose three times a day with telephone follow up every two weeks. A quality of life survey (DASI) is completed at four separate times during the enrollment period.
This IRB study is open to other qualifying Colloquium members. For more information, contact Tom VonderBrink (Bioenergy Life Science) at
tvonderbrink@bioenergy.com or 614 286 0392.
|